stoxline Quote Chart Rank Option Currency Glossary
  
Vyant Bio, Inc. (VYNT)
0.194  0.014 (7.78%)    12-29 15:39
Open: 0.18
High: 0.2
Volume: 19,116
  
Pre. Close: 0.18
Low: 0.175
Market Cap: 1(M)
Technical analysis
2024-01-12 4:54:46 PM
Short term     
Mid term     
Targets 6-month :  0.23 1-year :  0.27
Resists First :  0.2 Second :  0.23
Pivot price 0.17
Supports First :  0.17 Second :  0.15
MAs MA(5) :  0.17 MA(20) :  0.17
MA(100) :  0.17 MA(250) :  0.36
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  66.9 D(3) :  52.9
RSI RSI(14): 69.2
52-week High :  1.58 Low :  0.14
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VYNT ] has closed above the upper band by 23.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 27.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.2 - 0.2 0.2 - 0.2
Low: 0.17 - 0.17 0.17 - 0.17
Close: 0.19 - 0.19 0.19 - 0.2
Company Description

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Headline News

Fri, 19 Apr 2024
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% - Defense World

Tue, 26 Dec 2023
Vyant Bio Provides Update on Winddown Activities - GlobeNewswire

Fri, 10 Nov 2023
Vyant Bio Provides Update on Winddown Activities - Yahoo Finance

Fri, 10 Nov 2023
Vyant Bio expects to start liquidation payments in Q4 2024 (OTCMKTS:VYNT) - Seeking Alpha

Tue, 24 Oct 2023
Vyant Bio Announces Completion of StemoniX Asset Sale - Yahoo Finance

Thu, 19 Oct 2023
Vyant Bio Announces Stockholder Approval of Proposed Asset Sale - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 6 (M)
Held by Insiders 5.1e+006 (%)
Held by Institutions 18.7 (%)
Shares Short 179 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.328e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 400 %
Return on Equity (ttm) -51.8 %
Qtrly Rev. Growth 397000 %
Gross Profit (p.s.) -49.83
Sales Per Share -218.59
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.15
Stock Dividends
Dividend 0
Forward Dividend 204710
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android